ARCUS BIOSCIENCES INC - SEC FILING ANNOUNCES DISCONTINUATION OF STAR-121 AND PHASE 2 EDGE-LUNG STUDIES

Written by Emily J. Thompson, Senior Investment Analyst

Source: moomoo

Updated: 13 hours ago

0mins

RCUS-6.23%

GILD-1.29%

Should l Buy RCUS?

Source: moomoo

ARCUS Biosciences Updates: ARCUS Biosciences is continuing its studies on STAR-121 and Phase 2 Edge-Lung, focusing on advancements in their research and development efforts.
SEC Filing: The company has filed with the SEC, indicating ongoing regulatory compliance and transparency in its operations.

Trade with 70% Backtested Accuracy

Stop guessing "Should I Buy RCUS?" and start using high-conviction signals backed by rigorous historical data.

Analyst Views on RCUS

Wall Street analysts forecast RCUS stock price to rise

9 Analyst Rating

6 Buy

3 Hold

0 Sell

Moderate Buy

Current: 24.250

Low

14.00

Averages

27.44

High

44.00

Current: 24.250

Low

14.00

Averages

27.44

High

44.00

Leerink

Outperform

NULL

downgrade

$49 -> $47

2026-04-20

New

Reason

Leerink

Price Target

$49 -> $47

AI Analysis

2026-04-20

New

downgrade

Outperform

NULL

Reason

Leerink lowered the firm's price target on Arcus Biosciences to $47 from $49 and keeps an Outperform rating on the shares. The firm sees the end of Arcus' (RCUS) research collaboration with Gilead (GILD) as an opportunity for the company to pursue broader business development strategies with casdatifan and other pipeline candidates. While any change between a small company and their larger partner is worthy of reflection, Leerink is not surprised by the termination, as both companies have been moving away from their collaborative core in the last year. The firm finds it reassuring that Gilead maintained their equity position in Arcus and is retaining their two board seats.

Wedbush

NULL

Outperform

maintain

$37 -> $41

2026-04-02

Reason

Wedbush

Price Target

$37 -> $41

2026-04-02

maintain

NULL

Outperform

Reason

Wedbush raised the firm's price target on Arcus Biosciences to $41 from $37 and keeps an Outperform rating on the shares. The firm is also adding the stock to its Best Ideas List ahead of key clinical updates in 2026, including more mature data from the ARC-20 combination cohort evaluating HIF-2alpha inhibitor casdatifan plus cabozantinib in IO-experienced metastatic ccRCC patients that Wedbush expects to provide significant support to the ongoing Phase 3 PEAK-1, initial data evaluating cas in early line settings expected to support a TKI-free frontline Phase 3 in ccRCC by year-end 2026, and potential completion of Phase 3 PEAK-1 enrollment in 2026.

Unlock Full Analyst Thesis， Get the complete breakdown of rating reason for RCUS

Unlock Now

About RCUS

Arcus Biosciences, Inc. is a clinical-stage biopharmaceutical company developing differentiated molecules and combination therapies for people with cancer. The Company has a portfolio of investigational products, which are in clinical development with its advanced molecule, an anti-TIGIT antibody targeting lung and gastrointestinal cancers. The Company has approximately seven clinical programs that are focused on targets, including TIGIT, PD-1, adenosine A2a and A2b receptors, CD73, CD39, HIF-2a, and AXL. The Company is engaged in co-developing four investigational products, including zimberelimab (Arcuss anti-PD-1 molecule), domvanalimab (Arcuss anti-TIGIT antibody), etrumadenant (Arcuss adenosine receptor antagonist) and quemliclustat (Arcuss CD73 inhibitor). It is engaged in pursuing a Phase II and Phase III development program for domvanalimab in combination with its anti-PD-1 antibody, zimberelimab, in multiple settings, including lung and gastrointestinal cancer.

About the author

Emily J. Thompson

Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.

Arcus Biosciences Halts Late-Stage Lung Cancer Trial

11 hours agoseekingalpha

Trial Termination Reason: Arcus Biosciences announced the discontinuation of the STAR-121 trial in collaboration with Gilead Sciences due to futility, indicating poor clinical prospects for the anti-TIGIT therapy domvanalimab, which may impact the company's future R&D direction.
Clinical Trial Details: The STAR-121 trial evaluated domvanalimab combined with chemotherapy and the anti-PD-1 antibody zimberelimab as a first-line treatment for metastatic non-small cell lung cancer, but the Independent Data Monitoring Committee's recommendation led to its early termination, revealing insufficient efficacy of the therapy.
Other Study Cessation: The company also announced the halt of the Phase 2 EDGE-Lung study, which assessed domvanalimab with various immunotherapies, further indicating significant challenges in its lung cancer research and potentially affecting its market competitiveness.
Collaboration Rights Change: Arcus disclosed that effective July 14, 2026, Gilead will no longer hold option rights to certain early-stage pipeline projects due to the non-payment of option continuation fees, which may impact Arcus's cash flow and future collaboration opportunities.